{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:35:27Z","timestamp":1789684527678,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.joca.2024.06.016","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T13:31:10Z","timestamp":1719840670000},"page":"1471-1480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in patients with symptomatic knee osteoarthritis"],"prefix":"10.1016","volume":"32","author":[{"given":"Asger R.","family":"Bihlet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Byrjalsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla","family":"Mundbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Rovsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Melton","family":"Axelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-5664","authenticated-orcid":false,"given":"Jeppe Ragnar","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Metnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bachtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1671-9277","authenticated-orcid":false,"given":"Alan","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alexandersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.joca.2024.06.016_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/BOR.0000000000000479","article-title":"Epidemiology of osteoarthritis: literature update","volume":"30","author":"Vina","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"Pt 1","key":"10.1016\/j.joca.2024.06.016_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/bj3260235","article-title":"Aggrecan degradation in human intervertebral disc and articular cartilage","volume":"326","author":"Sztrolovics","year":"1997","journal-title":"Biochem J"},{"issue":"1873-5592 (Electronic)","key":"10.1016\/j.joca.2024.06.016_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/138945010791011956","article-title":"Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis\u2014insights from studies of aggrecan and collagen proteolysis?","volume":"11","author":"Little","year":"2010","journal-title":"Curr Drug Targets"},{"issue":"8","key":"10.1016\/j.joca.2024.06.016_bib4","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.biocel.2013.05.007","article-title":"The SOD mimic MnTM-2-PyP(5+) reduces hyaluronan degradation-induced inflammation in mouse articular chondrocytes stimulated with Fe (II) plus ascorbate","volume":"45","author":"Campo","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.joca.2024.06.016_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.matbio.2018.01.021","article-title":"Design of peptide mimetics to block pro-inflammatory functions of HA fragments","volume":"78-79","author":"Hauser-Kawaguchi","year":"2019","journal-title":"Matrix Biol"},{"issue":"9","key":"10.1016\/j.joca.2024.06.016_bib6","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1021\/bm8006852","article-title":"Design of a synthetic collagen-binding peptidoglycan that modulates collagen fibrillogenesis","volume":"9","author":"Paderi","year":"2008","journal-title":"Biomacromolecules"},{"issue":"1878-7568 (Electronic)","key":"10.1016\/j.joca.2024.06.016_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.actbio.2011.12.029","article-title":"Synthesis and characterization of an aggrecan mimic","volume":"8","author":"Bernhard","year":"2012","journal-title":"Acta Biomater"},{"issue":"1522-9653 (Electronic)","key":"10.1016\/j.joca.2024.06.016_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2024.06.016_bib9","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.joca.2016.07.017","article-title":"Disease-modifying treatments for osteoarthritis ((DMOADs)) of the knee and hip: lessons learned from failures and opportunities for the future","volume":"24","author":"Karsdal","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"issue":"0004-3591 (Print)","key":"10.1016\/j.joca.2024.06.016_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.joca.2024.06.016_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","article-title":"OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited","volume":"12","author":"Pham","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2024.06.016_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.joca.2010.04.013","article-title":"Evaluating the responsiveness of the ICOAP following hip or knee replacement","volume":"18","author":"Davis","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2024.06.016_bib13","unstructured":"Hawker GA. Measure of Intermittent and Constant Osteoarthritis Pain: ICOAP User\u2019s Guide. Published online; 2010:3\u20135."},{"issue":"4","key":"10.1016\/j.joca.2024.06.016_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/annrheumdis-2020-217160","article-title":"Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative","volume":"80","author":"Bowes","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.joca.2024.06.016_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.semarthrit.2020.09.007","article-title":"A novel diclofenac gel (AMZ001) applied once or twice daily in subjects with painful knee osteoarthritis: a randomized, placebo-controlled clinical trial","volume":"50","author":"Bihlet","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.joca.2024.06.016_bib16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Mokhtarani","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.joca.2024.06.016_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/annrheumdis-2018-213336","article-title":"Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1\u03b1 and anti-interleukin-1\u03b2 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis","volume":"78","author":"Kloppenburg","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1878-7568 (Electronic)","key":"10.1016\/j.joca.2024.06.016_bib18","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1016\/j.actbio.2012.08.041","article-title":"Incorporation of an aggrecan mimic prevents proteolytic degradation of anisotropic cartilage analogs","volume":"9","author":"Sharma","year":"2013","journal-title":"Acta Biomater"},{"issue":"1","key":"10.1016\/j.joca.2024.06.016_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3810\/pgm.2013.01.2618","article-title":"Viscosupplementation in patients with osteoarthritis of the knee","volume":"125","author":"Cianflocco","year":"2013","journal-title":"Postgrad Med"},{"issue":"2","key":"10.1016\/j.joca.2024.06.016_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semarthrit.2015.04.011","article-title":"Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis","volume":"45","author":"Henrotin","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.joca.2024.06.016_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.joca.2023.04.001","article-title":"Evaluation of S201086\/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial","volume":"31","author":"Schnitzer","year":"2023","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"10.1016\/j.joca.2024.06.016_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/M19-0675","article-title":"Disease-modifying effects of a novel cathepsin k inhibitor in osteoarthritis: a randomized controlled trial","volume":"172","author":"Conaghan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.joca.2024.06.016_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-021-02622-8","article-title":"Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA","volume":"23","author":"McGuire","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2024.06.016_bib24","doi-asserted-by":"crossref","unstructured":"Bowes M, Brett A, Conaghan PG. Thu0425 Cost-effective Oa Trials Require Enrolment of Knees With Definite Joint Space Narrowing (Kellgren Lawrence 3); Data From 6,939 Knees From the Osteoarthritis Initiative. In: 2019:500.2\u2013501. doi:10.1136\/annrheumdis-2019-eular.6992.","DOI":"10.1136\/annrheumdis-2019-eular.6992"},{"issue":"1522-9653 (Electronic)","key":"10.1016\/j.joca.2024.06.016_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.joca.2013.10.018","article-title":"Osteoarthritis\u2014a case for personalized health care?","volume":"22","author":"Karsdal","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2024.06.016_bib26","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.joca.2021.02.077","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of senolytic molecule UBX0101 in the treatment of painful knee osteoarthritis","volume":"29","author":"Lane","year":"2021","journal-title":"Osteoarthritis Cartilage"},{"issue":"4","key":"10.1016\/j.joca.2024.06.016_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.joca.2007.07.008","article-title":"Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial","volume":"16","author":"Yang","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"issue":"5","key":"10.1016\/j.joca.2024.06.016_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2013.10.002","article-title":"Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis","volume":"43","author":"Bannuru","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.joca.2024.06.016_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106503","article-title":"What can be done to control the placebo response in clinical trials? A narrative review","volume":"107","author":"Evans","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.joca.2024.06.016_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1515\/sjpain-2019-0183","article-title":"Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?","volume":"20","author":"Vase","year":"2020","journal-title":"Scand J Pain"},{"issue":"2","key":"10.1016\/j.joca.2024.06.016_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41584-018-0123-4","article-title":"Intra-articular treatment options for knee osteoarthritis","volume":"15","author":"Jones","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.joca.2024.06.016_bib32","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/art.41315","article-title":"Lorecivivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: a phase II randomized trial","volume":"72","author":"Yazici","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.joca.2024.06.016_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","article-title":"A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis","volume":"29","author":"Yazici","year":"2021","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2024.06.016_bib34","first-page":"70","article-title":"Efficacy of intra-articular CNTX-4975 for knee osteoarthritis (OA) pain varies with radiographic presence of oa in the opposite knee","volume":"130","author":"Stevens","year":"2018","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.joca.2024.06.016_bib35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","article-title":"Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials","volume":"23","author":"Karsdal","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"8","key":"10.1016\/j.joca.2024.06.016_bib36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2106\/JBJS.17.00154","article-title":"Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain","volume":"100","author":"Conaghan","year":"2018","journal-title":"J Bone Joint Surg"},{"issue":"7","key":"10.1016\/j.joca.2024.06.016_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/art.40840","article-title":"A phase II trial of lutikizumab, an anti\u2013interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2024.06.016_bib38","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.joca.2018.02.561","article-title":"Study design of a phase I, placebo-controlled, First-in-human trial to assess safety and tolerability, immunogenicity, and pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody\u00ae, M6495, in healthy male subjects","volume":"26","author":"Balchen","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.joca.2024.06.016_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpdd.1042","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the ADAMTS-5 inhibitor GLPG1972\/S201086 in healthy volunteers and participants with osteoarthritis of the knee or hip","volume":"11","author":"van der Aar","year":"2022","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458424012718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458424012718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:39:12Z","timestamp":1762029552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458424012718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1063458424012718"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2024.06.016","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in patients with symptomatic knee osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2024.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Osteoarthritis Research Society International. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}